Skip to Main content Skip to Navigation
Journal articles

Human IgG1 antibodies suppress angiogenesis in a target-independent manner.

Sasha Bogdanovich 1 Younghee Kim 1 Takeshi Mizutani 1, 2 Reo Yasuma 1 Laura Tudisco 3 Valeria Cicatiello 3, 4 Ana Bastos-Carvalho 1 Nagaraj Kerur 1 Yoshio Hirano 1 Judit Baffi 1 Valeria Tarallo 1, 3 Shengjian Li 1 Tetsuhiro Yasuma 1, 2 Parthasarathy Arpitha 1 Benjamin Fowler 1 Charles Wright 1 Ivana Apicella 3 Adelaide Greco 5, 6 Arturo Brunetti 5, 6 Menotti Ruvo 7 Annamaria Sandomenico 7 Miho Nozaki 2 Ryo Ijima 2 Hiroki Kaneko 2 Yuichiro Ogura 2 Hiroko Terasaki 2 Balamurali Ambati 8, 9 Jeanette Leusen 10 Wallace Langdon 11 Michael Clark 12 Kathryn Armour Pierre Bruhns 13 J Sjef Verbeek 14 Bradley Gelfand 1 Sandro de Falco 3, 15, * Jayakrishna Ambati 1, *
* Corresponding author
1 University of Kentucky
2 Nagoya City University [Nagoya, Japan]
3 IGB-CNR - Institute of Genetics and Biophysics - “Adriano Buzzati-Traverso” [Naples, Italy]
4 BIO-KER (Multimedica Group) [Naples]
5 University of Naples Federico II
6 CEINGE - Biotecnologie Avanzate
7 CNR – Istituto di Biostrutture e Bioimmagini
8 University of Utah School of Medicine [Salt Lake City]
9 Salt Lake City Veterans Affairs Health Care System
10 University Medical Center [Utrecht]
11 UWA - The University of Western Australia
12 CAM - University of Cambridge [UK]
13 Anticorps en thérapie et pathologie - Antibodies in Therapy and Pathology
14 Leiden University Medical Center (LUMC)
15 IRCCS Multimedica
Abstract : Aberrant angiogenesis is implicated in diseases affecting nearly 10% of the world's population. The most widely used anti-angiogenic drug is bevacizumab, a humanized IgG1 monoclonal antibody that targets human VEGFA. Although bevacizumab does not recognize mouse Vegfa, it inhibits angiogenesis in mice. Here we show bevacizumab suppressed angiogenesis in three mouse models not via Vegfa blockade but rather Fc-mediated signaling through FcγRI (CD64) and c-Cbl, impairing macrophage migration. Other approved humanized or human IgG1 antibodies without mouse targets (adalimumab, alemtuzumab, ofatumumab, omalizumab, palivizumab and tocilizumab), mouse IgG2a, and overexpression of human IgG1-Fc or mouse IgG2a-Fc, also inhibited angiogenesis in wild-type and FcγR humanized mice. This anti-angiogenic effect was abolished by Fcgr1 ablation or knockdown, Fc cleavage, IgG-Fc inhibition, disruption of Fc-FcγR interaction, or elimination of FcRγ-initated signaling. Furthermore, bevacizumab's Fc region potentiated its anti-angiogenic activity in humanized VEGFA mice. Finally, mice deficient in FcγRI exhibited increased developmental and pathological angiogenesis. These findings reveal an unexpected anti-angiogenic function for FcγRI and a potentially concerning off-target effect of hIgG1 therapies.
Document type :
Journal articles
Complete list of metadata

Cited literature [95 references]  Display  Hide  Download
https://hal-pasteur.archives-ouvertes.fr/pasteur-02511158
Contributor : Marie Martin Connect in order to contact the contributor
Submitted on : Wednesday, March 18, 2020 - 3:28:48 PM
Last modification on : Wednesday, November 3, 2021 - 4:54:21 AM

File

Vignette du document
sigtrans20151.pdf
Publication funded by an institution

Licence

Distributed under a Creative Commons Attribution 4.0 International License

Identifiers

Collections

PASTEUR

Citation

Sasha Bogdanovich, Younghee Kim, Takeshi Mizutani, Reo Yasuma, Laura Tudisco, et al.. Human IgG1 antibodies suppress angiogenesis in a target-independent manner.. Signal Transduction and Targeted Therapy, Nature.com, 2016, 1, pp.15001. ⟨10.1038/sigtrans.2015.1⟩. ⟨pasteur-02511158⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Les métriques sont temporairement indisponibles